Lacosamide Tablet, Film Coated
Product Images NDC 80425-0510

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 80425-0510). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lacosamide 50mg #30 (Lacosamide 50mg 80425 0510 01)

Lacosamide 50 mg film-coated tablets packaging label from Advanced Rx of Tennessee, LLC, Nashville, TN. The label includes the product name, dosage strength, quantity (#30 tablets), NDC 80425-0510-01, lot number, expiration date 12/31/2026, and a barcode. It also contains storage instructions (20°-25°C) and a caution about the federal transfer restriction for the drug.*

FDA Label Image

Lacosamide 50mg #60 (Lacosamide 50mg 80425 0510 02)

Lacosamide 50 mg film-coated tablet carton label from Advanced Rx of Tennessee, LLC, Nashville, TN. The label includes storage instructions (20°-25°C), prescription use caution, NDC 80425-0510-02, and package size of 60 tablets. It references comparison to VIMPAT and includes lot and expiration date placeholders.*

FDA Label Image

Lacosamide 50mg #90 (Lacosamide 50mg 80425 0510 03)

Lacosamide 50 mg film-coated tablet label from Advanced Rx of Tennessee, LLC. The label includes packaging and storage instructions for maintaining 20°-25°C (68°-77°F), a barcode, C-V schedule classification, and a caution statement about lawful drug transfer. The label lists NDC 80425-0510-03 and references comparison to Vimpat.*

FDA Label Image

Laco-fig1.jpg (Laco Fig1)

A bar chart depicting median percent reduction in seizure frequency over 28 days from baseline to maintenance phase by dose in three studies. Each study compares seizure reduction percentages for placebo and multiple doses of Lacosamide (ranging from 200 mg/day to 600 mg/day). Values show notable increases in seizure reduction with Lacosamide versus placebo, with some results marked as statistically significant.*

FDA Label Image

Laco-fig2.jpg (Laco Fig2)

A line graph titled 'Proportion of Patients by Responder Rate for Lacosamide and Placebo Groups in Studies 2, 3, and 4' showing responder rate (equal to or greater improvement) on the vertical axis and percent of patients on the horizontal axis. It compares placebo and lacosamide at 200 mg/day, 400 mg/day, and 600 mg/day across patient percentages from 0 to 100%, illustrating trends in patient response rates for each group.*

FDA Label Image

Laco-fig3-a (Laco Fig3 A)

A Kaplan-Meier survival curve graph comparing the proportion of patients over time (days) between Lacosamide and placebo groups. The graph shows two labeled lines representing Lacosamide (N=118) and placebo (N=121), with the number of patients at risk displayed at intervals below the x-axis. Statistical values including p-value, hazard ratio (HR), and 95% confidence interval (CI) are noted on the chart.*

FDA Label Image

Laco-str (Laco Str)

Chemical structure of lacosamide, depicting its molecular connectivity including an amide group, an aromatic phenyl ring, and other functional groups as represented by standard chemical notation.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.